Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $2.20 billion. The enterprise value is $1.19 billion.
| Market Cap | 2.20B |
| Enterprise Value | 1.19B |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 142.54 million shares outstanding. The number of shares has increased by 9.43% in one year.
| Shares Outstanding | 142.54M |
| Shares Change (YoY) | +9.43% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 13.77% |
| Owned by Institutions (%) | 79.49% |
| Float | 120.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.61 |
| Forward PS | 39.58 |
| PB Ratio | 2.12 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.65, with a Debt / Equity ratio of 0.04.
| Current Ratio | 13.65 |
| Quick Ratio | n/a |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -13.50% and return on invested capital (ROIC) is -18.28%.
| Return on Equity (ROE) | -13.50% |
| Return on Assets (ROA) | -11.40% |
| Return on Capital (ROIC) | -18.28% |
| Revenue Per Employee | $742,766 |
| Profits Per Employee | -$326,346 |
| Employee Count | 445 |
| Asset Turnover | 0.26 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $30,000 in taxes.
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.38% in the last 52 weeks. The beta is 1.33, so DNLI's price volatility has been higher than the market average.
| Beta (1Y) | 1.33 |
| 52-Week Price Change | -37.38% |
| 50-Day Moving Average | 19.01 |
| 200-Day Moving Average | 20.78 |
| Relative Strength Index (RSI) | 27.28 |
| Average Volume (30 Days) | 1,256,782 |
Short Selling Information
The latest short interest is 9.58 million, so 6.72% of the outstanding shares have been sold short.
| Short Interest | 9.58M |
| Short Previous Month | 9.41M |
| Short % of Shares Out | 6.72% |
| Short % of Float | 7.97% |
| Short Ratio (days to cover) | 9.30 |
Income Statement
In the last 12 months, DNLI had revenue of $330.53 million and -$145.22 million in losses. Loss per share was -$1.06.
| Revenue | 330.53M |
| Gross Profit | 330.53M |
| Operating Income | -196.70M |
| Pretax Income | -145.19M |
| Net Income | -145.22M |
| EBITDA | -128.47M |
| EBIT | -145.19M |
| Loss Per Share | -$1.06 |
Balance Sheet
The company has $1.03 billion in cash and $44.98 million in debt, giving a net cash position of $989.53 million or $6.94 per share.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 44.98M |
| Net Cash | 989.53M |
| Net Cash Per Share | $6.94 |
| Equity / Book Value | 1.03B |
| Book Value Per Share | 7.23 |
| Working Capital | 986.16M |
Cash Flow
In the last 12 months, operating cash flow was -$357.99 million and capital expenditures -$12.94 million, giving a free cash flow of -$370.93 million.
| Operating Cash Flow | -357.99M |
| Capital Expenditures | -12.94M |
| Free Cash Flow | -370.93M |
| FCF Per Share | -$2.70 |
Margins
Gross margin is 100.00%, with operating and profit margins of -59.51% and -43.94%.
| Gross Margin | 100.00% |
| Operating Margin | -59.51% |
| Pretax Margin | -43.93% |
| Profit Margin | -43.94% |
| EBITDA Margin | -38.87% |
| EBIT Margin | -43.93% |
| FCF Margin | -112.22% |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.43% |
| Shareholder Yield | -9.43% |
| Earnings Yield | -6.65% |
| FCF Yield | -16.98% |
Analyst Forecast
The average price target for DNLI is $45.44, which is 194.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.44 |
| Price Target Difference | 194.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 15.64% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNLI has an Altman Z-Score of 10.2 and a Piotroski F-Score of 3.
| Altman Z-Score | 10.2 |
| Piotroski F-Score | 3 |